Foundation for Neglected Disease Research (FNDR) is a unique not for profit R&D organization dedicated to developing novel therapeutics, diagnostics, and devices for diseases with a high socio-economic impact.
Since its inception in 2014, FNDR has generated a portfolio of therapeutics in tuberculosis, malaria, dengue, leishmania, serious bacterial infections, and recently, COVID-19, spanning over early-stage discovery to late-stage clinical trials. FNDR's R&D centre, which includes state-of-the-art BSL2 and BSL3 laboratories for both in vitro and in vivo research, is in Bengaluru, India.
FNDR is incorporated as a charitable “Not for Profit” company under section 8 of the Indian Companies Act, 2013.
Foundation for Neglected Disease Research (FNDR), Bangalore, India, has been awarded funding from the Cystic Fibrosis Foundation for preclinical development of a novel bactericidal therapeutic that has the potential to treat non-tuberculous mycobacterial (NTM) infections in people with cystic fibrosis (CF). The novel molecule is jointly owned by FNDR and National Centre for Polar and Ocean Research (NCPOR), Goa, India.
Dr. Shridhar Narayanan, CEO of FNDR, said “FNDR is proud to be the first Indian organization to receive a drug development award funding from the CF Foundation. We remain committed to discovering and developing new and better cures for infectious diseases.”
Tuberculosis (TB) is one of the leading causes of death by infectious diseases worldwide. In 2011, the WHO estimates that 8.7 million became infected with TB, and 1.4 million people succumbed to this disease. Over 95% of cases and deaths are in developing countries, with about 80% of reported TB cases..DETAILS
Neglected Tropical Diseases (NTDs) are a group of parasitic and bacterial diseases that cause substantial illness for more than one billion people globally. NTDs affect the world’s poorest people, impair their physical and cognitive development, contributeDETAILS
Foundation for Neglected Disease Research ( “FNDR”) is a charitable “Not for Profit” company incorporated under section 8 of the Companies Act, 2013, in Bengaluru (Bangalore), Karnataka, India, on September 1, 2014 to facilitate discovery of new medicines for the treatment of neglected diseases with global impact on global health.